TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in pre-post treatment Ki67 labeling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in post-treatment adjacent DCIS Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum standardized uptake value of adrenal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's Depression Rating Scale -- Revised (CDRS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in atrophic lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of a respiratory complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of a cardiovascular complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of an infectious complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: static compliance of the respiratory system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oxygen transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dead space fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Seroconversion rate (2-fold increase rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative analgesia (oxycodone consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: PGT-A Knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Seroprevalence of SARS-CoV-2 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Termination of AF during ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative liver failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking speed (m/s) as measured by the 10-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ability to activate the muscle that lifts the toes during the swing-phase of walking as measured by tibialis anterior EMG amplitude (mv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Viral exposure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of substance use score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quantity and quality of liver regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance measured by participation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of life (QOL) - anxiety & depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in emotion dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in decentering
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gastrointestinal symptoms evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Aberrant Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-Weighted Change in Log10 SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Hospitalizations and/or ER Visits Related to COVID-19 or Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in temperature of the left lumbar region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in temperature of the right lumbar region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knowledge about hazardous effects of drug abuse
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of the PYTHEAS® ODYSSEE device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of solicited adverse events within 7 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 14 after the booster vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of systemic inflammatory response (CRP and IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Quantitative Myasthenia Gravis (QMG) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodialysis Symptoms Distress-22 scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Eye closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lagophthalmos reduction in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prospective memory test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of invasive mold infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality from invasive mold infection
Endpoint domain: Mortality/survival
Primary endpoint: Time-matched change-from-baseline Fridericia's correction of QT interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of the analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Binocular Distance-corrected Near Visual Acuity (DCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Review of AEs likely related to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with active TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mortality in patients hospitalized for subarachnoid hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Stanford Acute Stress Reaction Questionnaire (SASRQ-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful reperfusion of the occluded target vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tinnete scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Gait index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma TNF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CSF TNF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean duration to require first rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family functioning and change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Eating disorder symptom impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perfusion index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year postoperative retreatment-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of PSA measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in uncorrected near visual acuity (UCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory viruses detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of swallowing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Klotho serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with post operative healthcare associated infection
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-reported compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in patient rate to category 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of youth who complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of patients permanently discontinuing cabozantinib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hydrogen fermentation in the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Small Intestine microbial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of natural clearance of Bordetella pertussis colonisation (nasal wash)
Endpoint domain: Physiological/clinical
Primary endpoint: Rate of natural clearance of Bordetella pertussis colonisation (nasopharyngeal swab)
Endpoint domain: Physiological/clinical
Primary endpoint: Castration resistant-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Quick Disabilities of the Arm, Shoulder, and Hand (Q-DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mobile App Sustain Use (MASU)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mobile App Intention Use (MAIU)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mobile App Satisfaction assessment (MAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evaluation of Pelvic Floor Muscle Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: International Consultation on Incontinence Questionnaire Short Form ICIQ-SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Constipation Quality of Life Scale (CIQS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cerebrovascular Insult (CVI)
Endpoint domain: Mortality/survival
Primary endpoint: Fold changes in number of basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold changes in number of innate immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold changes of IL-5R expression in basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold changes of IL-5R expression in innate lymphoid cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDSS uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with cured wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of relapse within two years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of COVID-19 IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: complete pathological response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantification of CIC structure in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility for completed treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stimulation intensity tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cholangitis caused by MDR pathogens
Endpoint domain: Adverse events/effects
Primary endpoint: Change in LDL-C percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean pain relief rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regional anesthesia success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Attributions change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental competency change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maternal depression change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal bonding change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive stimulation in the home change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dynamic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CMV viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of CMV disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death
Endpoint domain: Mortality/survival
Primary endpoint: CD8 T cell absolute number after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8 T cell cytotoxicity against cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8 T cell phenotype after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Center of Mass (CoM) excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative R0 resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Seroconversion From a Negative to a Positive Result for Serum IgG Against Antigens not Encoded by mRNA-1647
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma-Concentration Curves (AUC) of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brown adipose tissue metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in gut peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in μ-opioid receptors in the human brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appropriateness of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: spleen volume reduction (SVR35)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total symptom score reduction (TSS50)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Family engagement in care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Occupational Balance
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Anxiety, Depression and Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Academic stress
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of participants citing words about awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of participants citing words about meaning and subjective perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of participants citing words about implications on present and future history
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in engaging in perspective-taking related to rejection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in resilience capacity given social rejection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in satisfaction with close relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in motivation to interact socially
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in PA Enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PA session satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bt-DUX scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Revised UCLA Loneliness Scale (short form)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Muscle Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free survival (3y)
Endpoint domain: Mortality/survival
Primary endpoint: Jerk from the centre of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter-related urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Characterization and Incidence in Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of OP-1250 and Palbociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Median Observed Plasma Concentration at the End of a Dosing Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Serum Concentration at Steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression symptoms at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in patient-reported postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of the study design
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of the study design
Endpoint domain: Resource use
Primary endpoint: Prevalence of moderate to high hyperopia (≥ +2.00D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in near visual acuity on prescribing hyperopic spectacle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in fluorothymidine F-18 (18F-FLT) PET/CT uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported level of activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Characterization of leukocyte subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Offspring sex ratio
Endpoint domain: Mortality/survival
Primary endpoint: Change in Clinical health - Clinical Global Impression Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-assessed health - Patient Global Impression of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The change in severity of the functional movement disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change in tremor severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of cosmetic appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Same-day Discharge Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence rate of major congenital malformations at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline to day 7 of plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to 6 weeks of plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to day 7 of total body water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline to 6 weeks total body water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived voice effort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CRE clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of occlusion alarms generated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning